Content
All Posts > Content under Pharma/Biotech
Week In Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO On January 16
Article By:
ChinaBio® Today
Read
Sunday, January 5, 2020 10:20 AM EDT
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.
What A Difference A Year Makes! Only 10 Pot Stocks Now Have $1B+ Market Caps
Article By:
Lorimer Wilson
Read
Friday, January 3, 2020 4:56 AM EDT
At the height of the cannabis stock frenzy back in March/April there were 17 companies listed on the various stock exchanges with valuations over $1 billion; now, only 10.
Week In Review: Geneseeq And Elpiscience Close $100 Million VC Rounds; Zai Lab's PARP Inhibitor Approved For China Use
Article By:
ChinaBio® Today
Read
Saturday, December 28, 2019 4:12 PM EDT
Geneseeq, a Nanjing-Toronto company offering genetic sequencing tests for cancer, completed a $114 million Series D financing led by China Reform Holdings Corporation. Geneseeq uses next-gen sequencing to provide decision-making tools for doctors.
Flexion Price Target Raised To $25 From $19 At Benchmark
Article By:
The Fly
Read
Friday, December 27, 2019 11:16 AM EDT
Benchmark analyst Bruce Jackson raised his price target for Flexion Therapeutics to $25 from $19 after the company received FDA approval to update the product label for Zilretta for the treatment of osteoarthritis knee pain.
In this article: FLXN
Why Is This Stock Going Up When Financials Are Down
Article By:
Investing Whisperer
Read
Sunday, December 22, 2019 5:36 PM EDT
Stereotaxis is a medical device company with flat to declining revenue…yet the stock has quadrupled in 2019. The stock has more to do with a competitive takeover at 60x sales than its own financials.
IWM Waking Up Could Spark SPY, QQQ And Dow Rally
Article By:
Michele Schneider
Read
Sunday, December 22, 2019 1:00 PM EDT
Should the Russell 2000 IWM wake up, the rally in SPY, QQQs, and the Dow would be exponential. Furthermore, it would be the healthiest sign for the market since September 2018, right before the 20% sell-off.
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Article By:
ChinaBio® Today
Read
Saturday, December 21, 2019 5:09 PM EDT
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.